Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Oncology, and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MME/Neprilysin drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MME/CD10 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View MME Products |
| Gene Delivery | MME/CD10 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based assays. |
View MME Products |
| Benchmark Ab | Anti-MME/CD10 (Recombinant Sequence) Recombinant positive control antibody for validation. |
View MME Products |
| Validator | MME/CD10 siRNA Set For target knockdown and specificity verification. |
View MME Products |
| Related Target A | ACE (Angiotensin-Converting Enzyme) Crucial counter-screening target for cardiovascular safety and dual-inhibitor selectivity. |
View ACE Products |
| Related Target B | ECE1 (Endothelin-Converting Enzyme 1) Synergistic metalloprotease target in vasoconstriction and peptide degradation pathways. |
View ECE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Selectivity vs. Homologs (ACE/ECE) | HEK293 expressed MME, ACE, and ECE1 proteins with native glycosylation and verified purity (>95%) for precise enzyme kinetics. |
| Cell-Based Conformation & Screening | Lentiviral vectors optimized for high-efficiency transduction to construct stable CD10-overexpressing cell lines. |
| Lack of Controls | Sequence-verified benchmark recombinant antibodies available for assay calibration and flow cytometry. |
| False Positives in Knockdown | Sequence-specific siRNA pools designed to validate phenotypic dependency and off-target profiles. |
Live Neprilysin/CD10/MME R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Neprilysin (MME/CD10) spans multiple therapeutic areas, from cardiovascular disease to oncology and neurodegeneration. In cardiovascular medicine, Neprilysin inhibition (primarily via small molecules like sacubitril in combination with angiotensin receptor blockers) remains a cornerstone of heart failure therapy. The next wave of R&D focuses on expanding these indications to kidney disease and developing multi-specific metalloprotease inhibitors that optimize the balance between vasodilation and safety.
Concurrently, in oncology, CD10 serves as a critical diagnostic marker and a therapeutic target for monoclonal antibodies and antibody-drug conjugates (ADCs) in hematological malignancies and select solid tumors. In neurodegeneration, particularly Alzheimer's disease, therapeutic strategies are exploring the upregulation or delivery of active Neprilysin to clear amyloid-beta plaques, requiring highly active, natively folded recombinant proteins to model degradation kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, AstraZeneca, Academic Leads | Heart Failure, Hypertension, Chronic Kidney Disease | Selectivity assays against ACE/ECE1 (Requires high-purity, natively folded HEK293 recombinant proteins) |
| Antibody-Drug Conjugates (ADCs) | Biotech Innovators, Oncology Consortia | Acute Lymphoblastic Leukemia, Solid Tumors | Internalization and binding assays (Requires sequence-verified CD10 antigens and positive control antibodies) |
| Recombinant Protein Therapeutics | Neurodegenerative Research Institutes | Alzheimer's Disease | Amyloid-beta cleavage kinetics (Requires endotoxin-controlled, highly active enzymatic preparations) |